WO2002087555A3 - Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer - Google Patents

Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer Download PDF

Info

Publication number
WO2002087555A3
WO2002087555A3 PCT/EP2002/004771 EP0204771W WO02087555A3 WO 2002087555 A3 WO2002087555 A3 WO 2002087555A3 EP 0204771 W EP0204771 W EP 0204771W WO 02087555 A3 WO02087555 A3 WO 02087555A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
bisphosphonates
prostate cancer
bone metastasis
metastasis associated
Prior art date
Application number
PCT/EP2002/004771
Other languages
French (fr)
Other versions
WO2002087555A2 (en
Inventor
John J Seaman
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
John J Seaman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP02727586A priority Critical patent/EP1418897A2/en
Priority to CA002443625A priority patent/CA2443625A1/en
Application filed by Novartis Ag, Novartis Pharma Gmbh, John J Seaman filed Critical Novartis Ag
Priority to NZ528676A priority patent/NZ528676A/en
Priority to IL15827302A priority patent/IL158273A0/en
Priority to MXPA03010007A priority patent/MXPA03010007A/en
Priority to JP2002584901A priority patent/JP2004528340A/en
Priority to US10/476,365 priority patent/US20040157799A1/en
Priority to KR10-2003-7014244A priority patent/KR20040015230A/en
Priority to PL02363507A priority patent/PL363507A1/en
Priority to SK1351-2003A priority patent/SK13512003A3/en
Priority to HU0400096A priority patent/HUP0400096A2/en
Priority to BR0209365-0A priority patent/BR0209365A/en
Priority to AU2002257802A priority patent/AU2002257802B2/en
Publication of WO2002087555A2 publication Critical patent/WO2002087555A2/en
Priority to NO20034877A priority patent/NO20034877L/en
Publication of WO2002087555A3 publication Critical patent/WO2002087555A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

A method for the treatment of prostate cancers and other cancers having associated osteoblastic (osteosclerotic) metastases in a patient in need of such treatment comprising administering an effective amount of an N-bisphosphonate, especially zoledronic acid or a salt or any hydrate thereof, to the patient.
PCT/EP2002/004771 2001-05-02 2002-04-30 Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer WO2002087555A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
PL02363507A PL363507A1 (en) 2001-05-02 2002-04-30 Pharmaceutical uses of bisphosphonates
KR10-2003-7014244A KR20040015230A (en) 2001-05-02 2002-04-30 Pharmaceutical uses of bisphosphonates
NZ528676A NZ528676A (en) 2001-05-02 2002-04-30 Use of bisphosphonates in the treatment of bone metastases associated with prostate cancer
CA002443625A CA2443625A1 (en) 2001-05-02 2002-04-30 Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
MXPA03010007A MXPA03010007A (en) 2001-05-02 2002-04-30 Pharmaceutical uses of bisphosphonates.
JP2002584901A JP2004528340A (en) 2001-05-02 2002-04-30 Pharmaceutical use of bisphosphonates
SK1351-2003A SK13512003A3 (en) 2001-05-02 2002-04-30 Pharmaceutical uses of bisphosphonates
EP02727586A EP1418897A2 (en) 2001-05-02 2002-04-30 Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
IL15827302A IL158273A0 (en) 2001-05-02 2002-04-30 Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
US10/476,365 US20040157799A1 (en) 2001-05-02 2002-04-30 Pharmaceutical uses of bisphosphonates
HU0400096A HUP0400096A2 (en) 2001-05-02 2002-04-30 Pharmaceutical uses of bisphosphonates
BR0209365-0A BR0209365A (en) 2001-05-02 2002-04-30 Pharmaceutical uses of bisphosphonates
AU2002257802A AU2002257802B2 (en) 2001-05-02 2002-04-30 Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
NO20034877A NO20034877L (en) 2001-05-02 2003-10-31 Use of biphosphonates in the treatment of bone metastasis associated with prostate cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28822001P 2001-05-02 2001-05-02
US60/288,220 2001-05-02

Publications (2)

Publication Number Publication Date
WO2002087555A2 WO2002087555A2 (en) 2002-11-07
WO2002087555A3 true WO2002087555A3 (en) 2004-02-05

Family

ID=23106248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/004771 WO2002087555A2 (en) 2001-05-02 2002-04-30 Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer

Country Status (22)

Country Link
US (1) US20040157799A1 (en)
EP (1) EP1418897A2 (en)
JP (1) JP2004528340A (en)
KR (1) KR20040015230A (en)
CN (1) CN1277545C (en)
AR (1) AR033175A1 (en)
AU (1) AU2002257802B2 (en)
BR (1) BR0209365A (en)
CA (1) CA2443625A1 (en)
CZ (1) CZ20032950A3 (en)
HK (1) HK1080711A1 (en)
HU (1) HUP0400096A2 (en)
IL (1) IL158273A0 (en)
MX (1) MXPA03010007A (en)
MY (1) MY141584A (en)
NO (1) NO20034877L (en)
NZ (1) NZ528676A (en)
PL (1) PL363507A1 (en)
RU (1) RU2297229C2 (en)
SK (1) SK13512003A3 (en)
WO (1) WO2002087555A2 (en)
ZA (1) ZA200307666B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517242B2 (en) 2012-05-14 2016-12-13 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9522157B2 (en) 2012-05-14 2016-12-20 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9539268B2 (en) 2014-05-27 2017-01-10 Antecip Bioventures Ii Llc Therapeutic compositions comprising imidazole and imidazolium compounds
US9579323B2 (en) 2014-06-11 2017-02-28 Antecip Bioventures Ii Llc Compositions comprising RANK/RANKL antagonists and related compounds for treating pain
JP7136487B2 (en) 2013-10-25 2022-09-13 アンテシップ バイオベンチャーズ トゥー エルエルシー Oral pharmaceutical composition with enhanced oral bioavailability
US11851492B2 (en) 2014-09-17 2023-12-26 Merck Patent Gmbh Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
JP4838720B2 (en) * 2003-05-13 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Methods for modulating metastasis and skeletal related phenomena caused by metastasis
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
KR20060058134A (en) * 2003-09-19 2006-05-29 화이자 프로덕츠 인코포레이티드 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
ES2426445T3 (en) * 2006-04-07 2013-10-23 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US8999383B2 (en) * 2008-05-07 2015-04-07 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
RU2407746C2 (en) * 2008-09-29 2010-12-27 ЗАО "Фарм-Синтез" Radiopharmaceutical agent for diagnosing or treating (therapy) skeletal bone injuries and method of preparing said agent
CA2751854A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
CA2769633C (en) 2009-07-31 2017-06-06 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2289900A1 (en) * 2009-08-26 2011-03-02 Humboldt Universität zu Berlin Bisphosphonates as inhibitors of acid sphingomyelinase
SI2473172T1 (en) * 2009-09-01 2015-07-31 Duke University Bisphosphonate compositions and methods for treating heart failure
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2012094598A2 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9655908B2 (en) 2012-05-14 2017-05-23 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9694023B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9669040B2 (en) 2012-05-14 2017-06-06 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9616078B2 (en) 2012-05-14 2017-04-11 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9675626B2 (en) 2012-05-14 2017-06-13 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10173986B2 (en) 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US9427403B2 (en) 2012-05-14 2016-08-30 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9662343B2 (en) 2012-05-14 2017-05-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9289441B2 (en) 2014-08-08 2016-03-22 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9707245B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9700570B2 (en) 2014-05-27 2017-07-11 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9688765B2 (en) 2014-06-11 2017-06-27 Antecip Bioventures Ii Llc Methods using RANK/RANKL antagonist antibodies for treating pain
JO3394B1 (en) * 2014-07-04 2019-10-20 Osteo Pharma B V Compositions and products for use in the treatment of bone fractures and defects
CN107073111A (en) 2014-09-17 2017-08-18 默克专利股份公司 The method for treating solid carcinoma and/or method, its medicine and the predicted treatment solid carcinoma of its transfer and/or the clinical effectiveness of its transfer
CN107003298B (en) * 2014-11-27 2020-04-14 皇家飞利浦有限公司 Chemical analysis of urine and fecal vapors
RU2609871C1 (en) * 2015-08-10 2017-02-06 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Antitumor agent
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
CN108514645B (en) * 2018-04-08 2021-07-20 西南医科大学附属医院 Preparation with bone imaging and bone metastasis tumor treatment functions and preparation and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041725A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Therapeutic compositions for metabolic bone disorders or bone metastases
WO2000059485A2 (en) * 1999-04-07 2000-10-12 Novartis Ag Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor
WO2000071104A2 (en) * 1999-05-21 2000-11-30 Novartis Ag Use of bisphosphonic acids for treating angiogenesis
WO2002009631A1 (en) * 2000-07-27 2002-02-07 Umd, Inc. Vaginal delivery of bisphosphonates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634691A (en) * 1980-10-07 1987-01-06 The Procter & Gamble Company Method for inhibiting tumor metastasis
FI89364C (en) * 1990-12-20 1993-09-27 Leiras Oy FRUIT PROCESSING FOR METHYLENBISPHOSPHONE PHARMACEUTICALS, PHARMACOLOGICAL PROPERTIES
AU3677995A (en) * 1994-10-20 1996-05-15 Procter & Gamble Company, The Personal treatment compositions and/or cosmetic compositions containing enduring perfume
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6142383A (en) * 1998-04-08 2000-11-07 Hinsilblon Laboratories Method of waterless large scale dispersion of essential oils and apparatus therefor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041725A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Therapeutic compositions for metabolic bone disorders or bone metastases
WO2000059485A2 (en) * 1999-04-07 2000-10-12 Novartis Ag Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor
WO2000071104A2 (en) * 1999-05-21 2000-11-30 Novartis Ag Use of bisphosphonic acids for treating angiogenesis
WO2002009631A1 (en) * 2000-07-27 2002-02-07 Umd, Inc. Vaginal delivery of bisphosphonates

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
CLÉZARDIN P ET AL: "Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis.", JOINT, BONE, SPINE: REVUE DU RHUMATISME. FRANCE JAN 2000, vol. 67, no. 1, January 2000 (2000-01-01), pages 22 - 29, XP001097811, ISSN: 1297-319X *
FLEISCH H: "BISPHOSPHONATES PHARMACOLOGY AND USE IN THE TREATMENT OF TUMOUR- INDUCED HYPERCALCAEMIC AND METASTATIC BONE DISEASE", DRUGS, ADIS INTERNATIONAL LTD, AT, vol. 42, no. 6, 1991, pages 919 - 944, XP000676675, ISSN: 0012-6667 *
HAMDY N A T: "ROLE OF BISPHOSPHONATES IN METABOLIC BONE DISEASES", TRENDS IN ENDOCRINOLOGY AND METABOLISM, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 4, no. 1, 1993, pages 19 - 25, XP002906464, ISSN: 1043-2760 *
IWAMOTO JUN ET AL: "Transient relief of metastatic cancer bone pain by oral administration of etidronate.", JOURNAL OF BONE AND MINERAL METABOLISM. JAPAN 2002, vol. 20, no. 4, 2002, pages 228 - 234, XP001097829, ISSN: 0914-8779 *
MUNDY GREGORY R: "Mechanisms of bone metastasis.", CANCER, vol. 80, no. 8 SUPPL., 1997, pages 1546 - 1556, XP001094768, ISSN: 0008-543X *
NEMOTO R ET AL: "Effects of a new bisphosphonate (AHBuBP) on osteolysis induced by human prostate cancer cells in nude mice.", THE JOURNAL OF UROLOGY. UNITED STATES SEP 1990, vol. 144, no. 3, September 1990 (1990-09-01), pages 770 - 774, XP001097822, ISSN: 0022-5347 *
NEMOTO R ET AL: "INHIBITION BY A NEW BISPHOSPHONATE (YM175) OF BONE RESORPTION INDUCED BY THE MBT-2 TUMOUR OF MICE", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 67, no. 5, 1993, pages 893 - 897, XP000983665, ISSN: 0007-0920 *
POLLARD M ET AL: "Effects of dichloromethylene diphosphonate on the osteolytic and osteoplastic effects of rat prostate adenocarcinoma cells.", JOURNAL OF THE NATIONAL CANCER INSTITUTE. UNITED STATES NOV 1985, vol. 75, no. 5, November 1985 (1985-11-01), pages 949 - 954, XP001094384, ISSN: 0027-8874 *
POLLARD M ET AL: "Effects of diphosphonate and x-rays on bone lesions induced in rats by prostate cancer cells.", CANCER. UNITED STATES 15 MAY 1988, vol. 61, no. 10, 15 May 1988 (1988-05-15), pages 2027 - 2032, XP001098093, ISSN: 0008-543X *
POLLARD M ET AL: "The beneficial effects of diphosphonate and piroxicam on the osteolytic and metastatic spread of rat prostate carcinoma cells.", THE PROSTATE. UNITED STATES 1986, vol. 8, no. 1, 1986, pages 81 - 86, XP001097820, ISSN: 0270-4137 *
SHIPMAN C M ET AL: "ANIT-TUMOUR ACTIVITY OF BISPHOSPHONATES IN HUMAN MYELOMA CELLS", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 32, no. 1/2, 1998, pages 129 - 138, XP000980146, ISSN: 1042-8194 *
STEARNS M E ET AL: "Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice.", CLINICAL & EXPERIMENTAL METASTASIS. NETHERLANDS NOV 1998, vol. 16, no. 8, November 1998 (1998-11-01), pages 693 - 702, XP001098092, ISSN: 0262-0898 *
STEARNS M E ET AL: "EFFECTS OF ALENDRONATE AND TAXOL ON PC-3 ML CELL BONE METASTASES INSCID MICE", INVASION METASTASIS, S. KARGER, BASEL, CH, vol. 16, no. 3, 1996, pages 116 - 131, XP000946388, ISSN: 0251-1789 *
SUN YU-CHENG ET AL: "Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates.", JOURNAL OF UROLOGY, vol. 148, no. 4, 1992, pages 1270 - 1273, XP001097821, ISSN: 0022-5347 *
VIRTANEN SANNA S ET AL: "Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.", CANCER RESEARCH, vol. 62, no. 9, 1 May 2002 (2002-05-01), May 1, 2002, pages 2708 - 2714, XP001093993, ISSN: 0008-5472 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517242B2 (en) 2012-05-14 2016-12-13 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9522157B2 (en) 2012-05-14 2016-12-20 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9585901B2 (en) 2012-05-14 2017-03-07 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9585902B2 (en) 2012-05-14 2017-03-07 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
JP7136487B2 (en) 2013-10-25 2022-09-13 アンテシップ バイオベンチャーズ トゥー エルエルシー Oral pharmaceutical composition with enhanced oral bioavailability
US9539268B2 (en) 2014-05-27 2017-01-10 Antecip Bioventures Ii Llc Therapeutic compositions comprising imidazole and imidazolium compounds
US9579323B2 (en) 2014-06-11 2017-02-28 Antecip Bioventures Ii Llc Compositions comprising RANK/RANKL antagonists and related compounds for treating pain
US11851492B2 (en) 2014-09-17 2023-12-26 Merck Patent Gmbh Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases

Also Published As

Publication number Publication date
CZ20032950A3 (en) 2004-06-16
KR20040015230A (en) 2004-02-18
IL158273A0 (en) 2004-05-12
RU2003133773A (en) 2005-02-10
CA2443625A1 (en) 2002-11-07
SK13512003A3 (en) 2004-08-03
US20040157799A1 (en) 2004-08-12
CN1638778A (en) 2005-07-13
CN1277545C (en) 2006-10-04
PL363507A1 (en) 2004-11-29
ZA200307666B (en) 2004-05-05
AR033175A1 (en) 2003-12-03
NZ528676A (en) 2006-03-31
NO20034877D0 (en) 2003-10-31
HUP0400096A2 (en) 2004-04-28
EP1418897A2 (en) 2004-05-19
WO2002087555A2 (en) 2002-11-07
BR0209365A (en) 2004-06-08
HK1080711A1 (en) 2006-05-04
JP2004528340A (en) 2004-09-16
AU2002257802B2 (en) 2006-02-16
RU2297229C2 (en) 2007-04-20
MXPA03010007A (en) 2004-02-12
NO20034877L (en) 2003-12-19
MY141584A (en) 2010-05-14

Similar Documents

Publication Publication Date Title
WO2002087555A3 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
EP0943331A3 (en) Formulations containing oxaliplatin
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2000040275A3 (en) The preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning
PL373302A1 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
BR0012568A (en) Phosphate transport inhibitors
BR0207443A (en) Method and dosage form for the treatment of tumors by administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
CA2534577A1 (en) Method for promoting bone growth
WO2003084611A8 (en) Depsipeptide for therapy of kidney cancer
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
UA72927C2 (en) Docetaxel-containing composition for treating hepatocellular carcinoma
UA83888C2 (en) Pharmaceutical composition of vinflunine for parenteral administration, preparation method thereof and use of same
AU2002313726A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
AU2002319223A1 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
AU2002253899A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
BR0212446A (en) Use of 4-pyridylmethylphthalazine for cancer treatment
WO2000035469A3 (en) hCG THERAPY FOR THE TREATMENT OF BREAST CANCER
AU1991901A (en) Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof
AU5434899A (en) Cancer treatment
WO2003047571A3 (en) Use of a kmo inhibitor for producing a pharmaceutical composition
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NO NZ OM PH PL PT RO RU SE SG SI SK TJ TM TN TR TT UA US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002727586

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003/07666

Country of ref document: ZA

Ref document number: 200307666

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 158273

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002257802

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 528676

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2443625

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1-2003-501085

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: PV2003-2950

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 13512003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/010007

Country of ref document: MX

Ref document number: 028092236

Country of ref document: CN

Ref document number: 1020037014244

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002584901

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10476365

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002727586

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-2950

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 528676

Country of ref document: NZ

WWR Wipo information: refused in national office

Ref document number: 2002727586

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002727586

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2003-2950

Country of ref document: CZ